Scarica l'app Stockscreener
24.36
0.06%
-0.0258
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché PFE Giù?
Forum
Previsione
Frazionamento azionario
Storia dei dividendi
Pfizer Inc Borsa (PFE) Ultime notizie
Press Release: Congressman Bill Huizenga Applauds Trump Administration and Pfizer's Agreement to Lower Drug Prices and Invest in U.S. - Quiver Quantitative
Pfizer CEO Says Vaccine Approvals Are Harder to Get Right Now - Bloomberg.com
Why Moderna Might Be a One-Hit Wonder - The Motley Fool
AstraZeneca joins Pfizer in most-favored nation pricing program - TechTarget
Advanced Ovarian Cancer Pipeline 2025: FDA Updates, Therapy Innovations, and Clinical Trial Landscape Analysis by DelveInsight | Pfizer, Daiichi Sankyo, Astellas Pharma, Jiangsu HengRui, Boehringer - Barchart.com
GSK Fights Pfizer's Bid To Nix COVID-19 Vaccine Patents - Law360
Pfizer CEO Reportedly Says US Pharmaceutical Industry Should Collaborate With Chinese Counterparts - MarketScreener
Pfizer touts Tukysa in front-line breast cancer after Phase III victory - Yahoo Finance
Pfizer touts new Phase III win for Tukysa in front-line breast cancer - The Pharma Letter
Wall Street's Most Accurate Analysts Spotlight On 3 Health Care Stocks With Over 3% Dividend Yields - Benzinga
Pfizer (PFE) CEO Advocates for Collaboration with China's Pharma Industry - GuruFocus
Pfizer (PFE) CEO Highlights China's Rapid Drug Development - GuruFocus
Pfizer CEO touts China's 'dramatic speed' in biopharma, calls for U.S. collaboration - Seeking Alpha
Day 7 of Loss Streak for Pfizer Stock with -10% Return (vs. -2.6% YTD) [10/14/2025] - Trefis
Pfizer: CN Biopharma Sector Shows Astonishing Growth; US Drug Industry Must Collaborate with CN - AASTOCKS.com
Pfizer CEO says US pharma industry needs to collaborate with China - Reuters
Lobbying Update: $30,000 of PFIZER INC. lobbying was just disclosed - Quiver Quantitative
Pfizer (PFE) Faces Continued Losses Despite Bullish Analyst Rati - GuruFocus
Is Pfizer’s Latest Drug Pricing Deal a Turning Point for 2025 Valuation? - simplywall.st
Pfizer CEO Urges US-China Collaboration In Pharma; Stock Drops For 7th Day As Traders Hold For Dividend Payout - Stocktwits
Pfizer (PFE) Receives a Buy from BMO Capital - The Globe and Mail
Pfizer Seeks Expanded Use Approval For Breast Cancer Drug - Benzinga
Pfizer's (PFE) Tukysa Achieves Key Milestone in Breast Cancer Tr - GuruFocus
Pfizer (PFE) Receives a Hold from Bernstein - The Globe and Mail
Pfizer succeeds in late-stage trial for Tukysa breast cancer drug as maintenance therapy - Seeking Alpha
Pfizer (PFE) Reports Positive Results from Key Breast Cancer Tri - GuruFocus
Pfizer Says Tukysa Combination as First-Line Maintenance Meets Main Goal in Breast Cancer Trial - MarketScreener
Tukysa combination significantly improves progression-free survival as first-line maintenance in HER2+ metastatic breast cancer in HER2CLIMB-05 trial - MarketScreener
Pfizer’s breast cancer drug shows promise in first-line treatment - Investing.com
Pfizer’s breast cancer drug shows promise in first-line treatment By Investing.com - Investing.com India
TUKYSA Combination Significantly Improves Progression-Free Survival as First-Line Maintenance in HER2+ Metastatic Breast Cancer in HER2CLIMB-05 Trial - Yahoo Finance
Day 6 of Loss Streak for Pfizer Stock with -9.6% Return (vs. -1.8% YTD) [10/13/2025] - Trefis
Pfizer’s (PFE) Pipeline and Dividend Yield Make it a Compelling Income Stock - Yahoo Finance
Trump's AstraZeneca Deal Echoes Pfizer Pact. Big Pharma's Political Headaches Are Easing. - Barron's
AZN Strikes Drug Pricing Deal With Trump, Gets 3-Year Tariff Reprieve - The Globe and Mail
Pfizer Reaches Agreement with U.S. Government to Lower Drug Costs - Contract Pharma
Lawsuits Claim Pfizer Failed to Warn of Brain Tumor Risk From Birth Control Shot - Truthout
Trump Secures Major Win as AstraZeneca Joins Pfizer in Lowering US Drug Prices - Medical Daily
Global markets live: Blackstone, Pfizer, Tesla, Stellantis, AstraZeneca… - MarketScreener
Pfizer stock rises as BMO Capital reiterates Outperform rating - Investing.com
How Pfizer Inc. (PFE) Affects Rotational Strategy Timing - news.stocktradersdaily.com
Investors Heavily Search Pfizer Inc. (PFE): Here is What You Need to Know - Yahoo Finance
IP Group shares fly on back of Metsera & Pfizer news - BusinessCloud
Verdence Capital Advisors LLC Increases Stake in Pfizer Inc. $PFE - MarketBeat
Pfizer To Highlight Advancements In Respiratory Health And Infectious Disease Research At IDWeek 2025 - TradingView
Griffin Asset Management Inc. Grows Holdings in Pfizer Inc. $PFE - MarketBeat
Pfizer to present infectious disease data at IDWeek 2025 - Investing.com
Concurrent Investment Advisors LLC Purchases 20,663 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer to Highlight Advancements in Respiratory Health and Infectious Disease Research at IDWeek 2025 - Business Wire
Vanguard Personalized Indexing Management LLC Grows Position in Pfizer Inc. $PFE - MarketBeat
Pfizer, Inc. (PFE) Stock Analysis: Exploring the 16% Upside Potential and Robust Dividend Yield - DirectorsTalk Interviews
Estrogen Blockers Market Is Booming Worldwide 2025-2032 | Pfizer Inc., Novartis AG, AstraZeneca PLC - openPR.com
IP Group in line for future royalties from Pfizer’s drug deal - Proactive Investors
FY2025 EPS Estimates for Pfizer Lowered by Cantor Fitzgerald - MarketBeat
Is Pfizer (NYSE:PFE) Using Too Much Debt? - Yahoo Finance
Cwm LLC Raises Stake in Pfizer Inc. $PFE - MarketBeat
Sippican Capital Advisors Has $2.25 Million Stock Holdings in Pfizer Inc. $PFE - MarketBeat
Means Investment CO. Inc. Sells 22,379 Shares of Pfizer Inc. $PFE - MarketBeat
Callan Family Office LLC Purchases 48,269 Shares of Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. (NYSE: PFE) Price Prediction and Forecast 2025-2030 (October 2025) - 24/7 Wall St.
Pfizer (PFE) Faces Challenges Amid Drug Pricing Push - GuruFocus
LaRuby May and team of attorneys file suit against Pfizer, claim negligence in premature release of sickle cell drug therapy - AFRO American Newspapers
Precision Trading with Pfizer Inc. (PFE) Risk Zones - news.stocktradersdaily.com
Pfizer's Deal on Drug Prices Gets Closer to the Right Idea - Advisor Perspectives
Guggenheim Keeps Their Buy Rating on Pfizer (PFE) - The Globe and Mail
Pfizer Inc. $PFE Shares Bought by Fifth Third Wealth Advisors LLC - MarketBeat
Drucker Wealth 3.0 LLC Sells 15,443 Shares of Pfizer Inc. $PFE - MarketBeat
Aberdeen Group plc Increases Position in Pfizer Inc. $PFE - MarketBeat
Pfizer Inc. | Pharmaceuticals, Vaccines & Company History | Britannica Money - Britannica
0.39%
2.13%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):